anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Loxoprofen
Trial phase: Phase 4
ATC code: M02AA31
SMILES: CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 76
Group description: Loxoprofen 60 mg tablet three times a day with meal for 2 weeks
Eligibility criteria:
Inclusion Criteria:

Healthy Volunteers

Exclusion Criteria:

Endoscopic evidence of ulceration, erosion or active bleeding etc. in the esophagus, stomach, pylorus and/or duodenum prior to treatment endoscopy
A history of gastrointestinal ulcer
Any use of celecoxib, nonsteroidal anti-inflammatory drugs (including aspirin), anti-ulcer medication, antacids, systemic steroids or antibiotics within four weeks prior to the first dose of study medication
Intervention: FLUTICASONE PROPIONATE
Trial phase: Phase 4
ATC code: D07AC17 | R01AD08 | R01AD58 | R03BA05
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks.

Fluticasone propionate
Eligibility criteria:
Inclusion Criteria:

Current or ex-smokers
Aged over 50years
FEV1/FVC ratio <0.7
FEV1<80% predicted
Improvement in FEV1 following short acting beta-agonist not greater than 15% and 200ml.

Exclusion Criteria:

Diagnosis of asthma, bronchiectasis or ABPA
Inability to perform study procedures or give informed consent
Known sensitivity to trial medications
Intervention: Prednisone
Trial phase: Phase 3
ATC code: A07EA03 | H02AB07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Corticosteroid

Prednisone: Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.

Pyridostigmine: Prior to randomization, pyridostigmine dosage increments will be made as needed for myasthenic symptoms and as tolerated according to a pre-specified dosage titration schedule. Following randomization, dose will remain constant.
Eligibility criteria:
Inclusion Criteria:

Weakness confined to the extra-ocular muscles, eyelid levator and eye closure with an ocular-QMG1 score ≥ 1
At least one of the following combinations of abnormal diagnostic testing: a) Elevated acetylcholine receptor antibody titers, (b) Abnormal repetitive nerve stimulation (> 10% decrement following slow repetitive nerve stimulation) of any nerve-muscle pair, (c) Abnormal jitter on single fiber or concentric needle electromyography in any muscle, (d) Positive ice test and brain MRI that demonstrates no central nervous system pathology that mimics ocular myasthenia, or (e) Positive Tensilon test and brain MRI that demonstrate no central nervous system pathology that mimics ocular myasthenia
Either no prior treatment with pyridostigmine, or participant has persistent ocular symptoms that are functionally limiting or troublesome despite treatment with pyridostigmine.
Age 18 years or older, male or female
Capable of providing informed consent and complying with study procedures
Identifiable primary care physician to assist with management of medical complications that may arise as a consequence of steroid therapy
Willing to be randomized to a trial of prednisone or placebo if symptoms respond inadequately to pyridostigmine.

Exclusion Criteria:

Disease duration (time since symptom onset) > 5 years
Treatment with prednisone or other corticosteroids within 90 days of randomization
Treatment with azathioprine, cyclosporine, mycophenolate mofetil or other immune suppressive medication since onset of MG unless dosages of these medications and/or duration of therapy with these medications are clinically insignificant in the judgment of the PI
Intravenous immunoglobulin or plasma exchange within 90 days of randomization
Prior thymectomy or history of thymoma
Contraindication to steroids (poorly controlled diabetes, glaucoma or hypertension, history of prior steroid intolerance, obesity [BMI > 39.9kg/m2] or a history of osteoporotic fracture)
Pregnant or lactating
Renal failure, active thyroid or hepatocellular disease, chronic infection, poorly controlled cardiac disease, unstable psychiatric illness, untreated major depression or any other illness that would, in the opinion of the treating neurologist, make it unsafe for the patient to participate in the trial
Receipt of another investigational drug within 30 days of Screening
Intervention: Nicotine bitartrate
Trial phase: Phase 2
SMILES: CN1CCCC1c1cccnc1.O.O.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 14
Group description: Healthy smokers with nicotine dependence

Nicotine bitartrate : 0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days

[123I]5-IA-85380 : up to 10 mCi of [123I]5-IA-85380, I.V. on each of two SPECT Scan days

NicVAX : 1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
Eligibility criteria:
Inclusion Criteria:

Current smoker who smokes at least 10-25 cigarettes a day
Good general health

Exclusion Criteria:

Subjects with a pacemaker or other ferromagnetic material in body.
Prior exposure to NicVAX or any other nicotine vaccine.
Use of systemic steroids or other immunosuppressive agent
History of significant neurological, cardiovascular, hepatic, endocrine, renal, liver, psychiatric or thyroid illness
Cancer or cancer treatment in last 5 years
HIV infection
Use of varenicline (Chantix), bupropion (Wellbutrin, Zyban), mecamylamine (Inversin), within 30 days prior to administration of NicVAX and for the duration of the study.
Inability to fulfill all visits and examination procedures for approximately 20 weeks.
Intervention: Ovral
Trial phase: Phase 3
SMILES: C#CC1(O)CCC2C3CCC4=CC(=O)CCC4C3CCC21CC.C#CC1(O)CCC2C3CCc4cc(O)ccc4C3CCC21C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 3597
Group description: Four 91-day cycles of the DR-103 regimen:

42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by;
21 days combination therapy of 25 mcg EE/150 mcg LNG followed by;
21 days combination therapy of 30 mcg EE/150 mcg LNG followed by;
7 days of 10 mcg EE.
Eligibility criteria:
Inclusion Criteria:

Sexually active at risk for pregnancy
Agreement to use study OC therapy as their only method of birth control during the study
history of regular spontaneous menstrual cycles or withdrawal bleeding episodes
Others as dictated by FDA-approved protocol

Exclusion Criteria:

Any contraindication to the use of oral contraceptives
Pregnancy or plans to become pregnant in the next 14 months
Smoker and age ≥ 35 years
Others as dictated by FDA-approved protocol
Intervention: Linagliptin
Trial phase: Phase 3
ATC code: A10BD11 | A10BD19 | A10BD27 | A10BH05
SMILES: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 183
Group description: Linagliptin 5 mg (milligrams) tablet given by mouth once daily
Eligibility criteria:
Inclusion criteria:

Diagnosis of diabetes mellitus prior to informed consent
Patients treated with metformin and pioglitazone (therapy should be unchanged for 12 weeks)
Glycosylated haemoglobin A1 >= 7.5% and <= 10%
Age between 18 and less than 80
- Body Mass index less or equal to 45

Exclusion criteria:

Uncontrolled hyperglycaemia during run in period
Myocardial infarction, stroke or transient ischaemic accident within 3 months prior to informed consent
Impaired hepatic function
Gastric by pass surgery
Treatment with roziglitazone, GLP 1 analogues, DPP-4 inhibitors or insulin within 3 months prior to informed consent
Treatment with anti-obesity drugs
Current treatment with systemic steroids at the time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent
Premenopausal women who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control or do not plan to continue using this method during the trial
Intervention: Cholecalciferol
Trial phase: Not Applicable
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: This is the study group that receives Vitamin D supplementation.

Vitamin D3: Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
Eligibility criteria:
Inclusion Criteria:

Healthy men or women between the ages of 18 and 70 years old who are enrolled in our Weight Management Program with baseline BMI > 30 Kg/m2.

Exclusion Criteria:

Pregnancy,
Serum 25(OH)D level greater than 80 nmol/L,
Hypercalcemia (serum calcium level greater than the upper limit of normal),
Recent surgery or illness,
Those with chronic use of medications that influence calcium/vitamin D metabolism such as anti-convulsants, lithium and steroids. Thiazide diuretics for hypertension will be acceptable.
Subjects with sarcoidosis will be excluded.
Those who do not qualify to participate in the Weight Management Program will be excluded. They include subjects with active substance abuse and unstable cardiac disease.
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: propofol only for deep procedural sedation

propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
Eligibility criteria:
Inclusion Criteria:

patients who will require deep procedural sedation with propofol in the ED

Exclusion Criteria:

age <18
intoxication
unable to provide informed consent
allergy to propofol or alfentanil
pregnant
ASA physical status score > 2
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 56
Group description: Propofol 1m g/kg IV followed by 0.5 mg/kg IV prn sedation

Propofol: Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
Eligibility criteria:
Inclusion Criteria:

Adults undergoing moderate procedural sedation in the Emergency Department

Exclusion Criteria:

Age <18 years
Pregnancy
Intoxication
Cannot give informed consent
Allergy to any of the three study medications
ASA physical status score > 2
Patients who require deep procedural sedation
Intervention: Alfentanil
Trial phase: Phase 4
ATC code: N01AH02
SMILES: CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: Sedation using alfentanil 10 ug/kg followed by 5 ug/kg prn sedation

Alfentanil: Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
Eligibility criteria:
Inclusion Criteria:

Adults undergoing moderate procedural sedation in the Emergency Department

Exclusion Criteria:

Age <18 years
Pregnancy
Intoxication
Cannot give informed consent
Allergy to any of the three study medications
ASA physical status score > 2
Patients who require deep procedural sedation
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: propofol 1 milligram per kilogram at the start of the procedure followed by 0.5 milligrams per kilogram every 3 minutes as needed for moderate procedural sedation
Eligibility criteria:
Inclusion Criteria:

patients who require moderate procedural sedation with propofol in the ED

Exclusion Criteria:

age > 17 years
pregnant
intoxicated
cannot give informed consent
allergy to ketamine or propofol
patient will require deep procedural sedation
ASA physical status score > 2
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: ketamine 1 milligram per kilogram intravenous bolus to start procedure followed by 0.5 mg/kg every three minutes as needed for moderate procedural sedation
Eligibility criteria:
Inclusion Criteria:

patients who require moderate procedural sedation with propofol in the ED

Exclusion Criteria:

age > 17 years
pregnant
intoxicated
cannot give informed consent
allergy to ketamine or propofol
patient will require deep procedural sedation
ASA physical status score > 2
Intervention: Letrozole
Trial phase: Not Applicable
ATC code: L02BG04
SMILES: N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: Letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy or re-biopsy.

Letrozole: 2.5 mg daily from the day of enrollment to the day before surgery (generally about 3 weeks) or to the day of repeat endometrial biopsy 9medical treatment arm).
Eligibility criteria:
Inclusion Criteria:

FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium
Post menopausal status must be demonstrated
Signed informed consent

Exclusion Criteria:

FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium
Younger than 40 or postmenopausal status not established
Pregnant or breastfeeding
Intervention: FLUTICASONE FUROATE
Trial phase: Phase 4
ATC code: R01AD12 | R03AK10 | R03AL08 | R03BA09
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)c3ccco3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 40
Group description: Active treatment

Fluticasone furoate Nasal Spray: Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo
Eligibility criteria:
Inclusion Criteria:

Symptomatic seasonal allergic rhinitis symptoms for at least 2 years at the time of study in the season of the study.
Allergy skin tests positive for the airborne allergens present at the study time within the past 12 months.
A score of 2 or more on the NRQLQ of the Rhinitis Quality of LIfe Questionnaire.
Active allergic rhinitis on 4 of 7 days during run-in week, and evidence on sleep scales of drowsiness on 3 of 7 days.
Ability to read, understand and give informed consent.
Ability to understand and carry out responsibilities of the study

Exclusion Criteria:

Any chronic disease or other acute disease, which could influence central nervous system.
The use of any medication, which could affect central nervous system function.
Unwillingness to participate in the study.
Inability to understand testing procedures or use of medication.
Hypersensitivity to fluticasone or vehicle of nasal sprays.
Any sleep disorders including obstructive sleep apnea.
Intervention: Teneligliptin
Trial phase: Phase 3
ATC code: A10BH08
SMILES: [H][C@@]1(N2CCN(c3cc(C)nn3-c3ccccc3)CC2)CN[C@]([H])(C(=O)N2CCSC2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 99
Group description: Teneligliptin 20 mg, orally, once daily
Eligibility criteria:
Inclusion Criteria:

Patients who are 20 - 75 years old
Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug
Patients whose HbA1c is between 6.5% - 10.0%
Patients who were not administered diabetes therapeutic drugs within 12 weeks before administration of investigational drug.

Exclusion Criteria:

Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)
Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification
Patients with serious diabetic complications.
Patients who are habitual excessive alcohol consumption.
Patients with severe hepatic disorder or severe renal disorder.
Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception
Intervention: CID 11593706
Trial phase: Not Applicable
SMILES: C=CCN.ClCC1CO1.O=C(O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Daily renvela with meals for 12 weeks

Sevelamer Carbonate: Daily renvela (800 mg tid with meals) x 12 weeks
Eligibility criteria:
Inclusion Criteria:

Inclusion criteria include pediatric patients, between the ages of 2 and 21 years, with CKD stages 2-4 (GFR 15-90 ml/min/1.73m2).

Exclusion Criteria:

Exclusion criteria include: the use of phosphate binder therapy within the past 3 months, treatment with 25(OH)vitamin D or 1,25dihydroxyvitamin D, underlying metabolic bone disease, or underlying renal phosphate wasting disorder.
Intervention: Tamoxifen
Trial phase: Phase 4
ATC code: L02BA01
SMILES: CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 127
Group description: Tamoxifen at a dose of 10 mg once daily from 5th day to 25th day of menstrual cycle for 3 months
Eligibility criteria:
Inclusion Criteria:

Clinical, Radiographic and Histological diagnosis of Benign Breast Disease.
Benign Breast disease amenable to hormonal therapy.

Exclusion Criteria:

Postmenopausal women.
Premenopausal women with pregnancy or other contraindications to tamoxifen.
Girls less than 16 years.
Very large lesions which require surgery for cosmesis.
High risk breast lesions like epitheliosis, atypia or atypical hyperplasia on histopathology or susceptible lesions prone to develop malignancy.
Lesions like duct ectasia where hormone therapy is not likely to be of benefit.
Inflammatory lesions which are amenable to antibiotic therapy or surgical drainage for treatment.
Patients unwilling to undergo treatment.
Intervention: Palmitic Acid
Trial phase: Phase 4
SMILES: CCCCCCCCCCCCCCCC(=O)O
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 129
Group description: Evening Primrose Oil at a dose of 1000 mg once daily for 3 months
Eligibility criteria:
Inclusion Criteria:

Clinical, Radiographic and Histological diagnosis of Benign Breast Disease.
Benign Breast disease amenable to hormonal therapy.

Exclusion Criteria:

Postmenopausal women.
Premenopausal women with pregnancy or other contraindications to tamoxifen.
Girls less than 16 years.
Very large lesions which require surgery for cosmesis.
High risk breast lesions like epitheliosis, atypia or atypical hyperplasia on histopathology or susceptible lesions prone to develop malignancy.
Lesions like duct ectasia where hormone therapy is not likely to be of benefit.
Inflammatory lesions which are amenable to antibiotic therapy or surgical drainage for treatment.
Patients unwilling to undergo treatment.
Intervention: Eltrombopag
Trial phase: Phase 2
ATC code: B02BX05
SMILES: CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: Starting dose 50 mg/day orally for 8 weeks

Eltrombopag: Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
Eligibility criteria:
Inclusion Criteria:

Patients >/= 35 days post HCT with Platelet count </= 20 x 10^9/l sustained for 7 days or patients are platelet transfusion dependent, and
Neutrophil count >/= 1.5 x 10^9/l anytime within the last seven days before enrollment. Patients can be on myeloid or erythroid growth factors for example filgrastim), and
Age >/= 18

Exclusion Criteria:

Recurrence or progression of primary malignancy after HCT
ALT >/= 2.5 times the ULN
Serum bilirubin >2mg/dl (unless due to Gilbert's syndrome)
Documented deep vein thrombosis within 1 year before enrollment on the study, except if upper arm thrombosis related to central venous catheters, within 3 months before enrollment on the study.
ECOG Performance status >2
Pregnancy: Women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation. A woman of child-bearing potential is defined as a woman who has not been naturally post-menopausal for at least 12 consecutive months or with no previous surgical sterilization. A negative pregnancy test result will be required before any study drug is given.
Intervention: Lisdexamfetamine Dimesylate
Trial phase: Phase 3
SMILES: CC(Cc1ccccc1)NC(=O)C(N)CCCCN.CS(=O)(=O)O.CS(=O)(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Drug: Vyvanse 30 mg for 7 days. 50 mg for 7 days. 70 mg for 28 days.
Eligibility criteria:
Inclusion Criteria:

Males and females, ages 16 to 45
Closed head injury rated as moderate/severe (based on Glasgow Coma Scale rating, estimated posttraumatic amnesia, etc.)
Sustained 6 to 36 months earlier, and considered to be neurologically stable
Persistent (> 6 months) problems with focused or sustained attention (+1 SD or worse on Inattention component of ADHD self ratings) corroborated by professional staff (nurses, therapists, etc.) or caregivers. Problems with attention/concentration rated as among most prominent cognitive changes.
Accompanying features may include diminished arousal/speed/stamina and/or disinhibited symptoms

Exclusion Criteria:

Penetrating head injury
Pre-injury history of diagnosed ADHD
Other psychiatric conditions such as mania or psychosis. Current posttraumatic stress disorder (PTSD) symptoms may be present but not so severe as to require pharmacologic treatment.
Lifetime history of psychostimulant abuse or dependence. Other (non-psychostimulant) substance abuse within the past 6 months. Total lifetime drug use will not exceed 5 times each for substances such as amphetamine, meth-amphetamine, or cocaine.
Prior treatment with psychostimulant(s)
Tics or other contraindications for psychostimulant use including arteriosclerosis, cardiovascular disease, uncontrolled hypertension or hyperthyroidism, glaucoma, agitation, use of MAO inhibitor within 6 weeks
Current treatment with other psychotropic medication(s) within the past 6 weeks
Estimated IQ < 80
Sensory and/or motor impairment(s) seriously limiting testing options
Other neurological conditions including epilepsy, degenerative disorders, brain tumor, or stroke.
Physical conditions affecting arousal, activity level or stamina, including uncontrolled thyroid dysfunction, anemia, autoimmune or metabolic disorders, untreated moderate/severe sleep apnea, etc.
Persons for whom MRI scanning is contraindicated, including weight greater than 275 pounds (due to scanner table limitations), severe claustrophobia, implanted electronic medical devices (e.g. pacemaker, cochlear or other inner ear implant, deep brain stimulator), metallic foreign object in eye or rest of the body, history of sheet metal work, aneurysm clips, non-removable metallic piercings, and dental prosthetics.